Companies › Shenyang Sunshine Pharmaceutical
12 active drug programs in 15 registered trials: 8 Phase 1, 6 Phase 2, 1 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SSGJ-707 | – | Phase 3 | Advanced Non-Small Cell Lung Cancer | Dec 2028 |
| SSGJ-705 Anti-PD-1 and anti-HER2 bispecific antibody | PDCD1, ERBB2 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid Tumors | Dec 2026 |
| SSGJ-612 HER2-targeting agent | ERBB2 | Phase 2 | Locally Advanced (Unresectable) or Metastatic Solid Tumors; Metastatic Breast Cancer; Advanced Malignant Tumors | Jun 2027 |
| SSGJ-706 PD-1/PD-L1 bispecific antibody | PDCD1, CD274 | Phase 2 | First-line Advanced NSCLC Patients | Aug 2027 |
| HER2-targeted ADC HER2-targeted antibody-drug conjugate | ERBB2 | Phase 2 | Metastatic Breast Cancer | Feb 2028 |
| SSS55 injection complement C3b inhibitor | C3 | Phase 1 | Safety Issues | Dec 2026 |
| SSS11 (Pegylated Recombinant Candida Utilis Uricase) Urate oxidase - converts uric acid to allantoin | XDH | Phase 1 | Gout | Dec 2026 |
| SSS59 humanized antibody targeting MUC17 | MUC17 | Phase 1 | Malignant Tumors | Mar 2027 |
| SPGL008 Biological product | – | Phase 1 | Advanced Malignant Tumors | Jun 2027 |
| HBT-708 bispecific antibody | – | Phase 1 | Advanced Solid Tumors | Jun 2027 |
| SSGJ-709 Bispecific antibody targeting PD-1 and LAG-3 | PDCD1, LAG3 | Phase 1 | Advanced Malignant Tumors | Sep 2027 |
| SSS40 Humanized nerve growth factor (NGF) antibody | NGF | Phase 1 | Cancer Pain | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07008703 | SSS40 | Phase 1 | Cancer Pain | Oncology | Dec 2025 |
| NCT07032298 | SSGJ-612 | Phase 1 | Advanced Malignant Tumors | Oncology | Apr 2026 |
| NCT07058779 | SSS55 injection | Phase 1 | Safety Issues | Other | Dec 2026 |
| NCT06629376 | SSS11 (Pegylated Recombinant Candida Utilis Uricase) | Phase 1 | Gout | Metabolic and endocrine | Dec 2026 |
| NCT07022002 | SSGJ-705 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies | Oncology | Dec 2026 |
| NCT06944444 | SSS59 | Phase 1 | Malignant Tumors | Oncology | Mar 2027 |
| NCT07038005 | SPGL008 | Phase 1 | Advanced Malignant Tumors | Oncology | Jun 2027 |
| NCT06993870 | HBT-708 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07646626 | SSGJ-612 | Phase 2 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT07646626 | SSGJ-705 | Phase 2 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT07171606 | SSGJ-706 | Phase 2 | First-line Advanced NSCLC Patients | Oncology | Aug 2027 |
| NCT07016490 | SSGJ-709 | Phase 1 | Advanced Malignant Tumors | Oncology | Sep 2027 |
| NCT07757230 | SSGJ-612 | Phase 2 | Metastatic Breast Cancer | Oncology | Feb 2028 |
| NCT07757230 | HER2-targeted ADC | Phase 2 | Metastatic Breast Cancer | Oncology | Feb 2028 |
| NCT06980272 | SSGJ-707 | Phase 3 | Advanced Non-Small Cell Lung Cancer | Oncology | Dec 2028 |
Shanghai Henlius Biotech Sichuan Baili Pharmaceutical DualityBio Shanghai Hengrui Pharmaceutical Akeso
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.